CytomX Therapeutics, Inc.
CTMX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 4.74 | 0.05 | 0.00 |
| FCF Yield | -2.93% | -5.39% | -38.20% | -24.23% |
| EV / EBITDA | -31.57 | -267.14 | 0.69 | 2.98 |
| Quality | ||||
| ROIC | -12.89% | -1.54% | 42.10% | 44.16% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.09 | 102.29 | -0.89 | -1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.25% | 21.08% | 29.71% | 37.47% |
| Free Cash Flow Growth | 2.28% | 25.43% | -5.87% | 3.66% |
| Safety | ||||
| Net Debt / EBITDA | 1.81 | 44.89 | -1.71 | -1.58 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 24.59 | -49.86 | 3.46 | 7.33 |